Free Trial

Avacta Group (AVCT) Competitors

Avacta Group logo
GBX 54
+4.00 (+8.00%)
(As of 11/1/2024 ET)

AVCT vs. ERGO, SLN, OXB, PRTC, HZD, VRP, FARN, ARIX, HVO, and 4BB

Should you be buying Avacta Group stock or one of its competitors? The main competitors of Avacta Group include Ergomed (ERGO), Silence Therapeutics (SLN), Oxford Biomedica (OXB), PureTech Health (PRTC), Horizon Discovery Group plc (HZD.L) (HZD), Verona Pharma plc (VRP.L) (VRP), Faron Pharmaceuticals Oy (FARN), Arix Bioscience (ARIX), hVIVO (HVO), and 4basebio (4BB). These companies are all part of the "biotechnology" industry.

Avacta Group vs.

Avacta Group (LON:AVCT) and Ergomed (LON:ERGO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, valuation, analyst recommendations, risk, media sentiment, earnings, dividends, community ranking and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Avacta Group
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Ergomed
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Ergomed has higher revenue and earnings than Avacta Group. Avacta Group is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avacta Group£22.62M8.55-£25.89M-£0.09-600.00
Ergomed£152.09M4.61£15M£0.294,641.38

Avacta Group has a beta of 1.12, indicating that its share price is 12% more volatile than the S&P 500. Comparatively, Ergomed has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Ergomed received 30 more outperform votes than Avacta Group when rated by MarketBeat users. Likewise, 75.63% of users gave Ergomed an outperform vote while only 67.30% of users gave Avacta Group an outperform vote.

CompanyUnderperformOutperform
Avacta GroupOutperform Votes
212
67.30%
Underperform Votes
103
32.70%
ErgomedOutperform Votes
242
75.63%
Underperform Votes
78
24.38%

10.2% of Avacta Group shares are held by institutional investors. Comparatively, 71.1% of Ergomed shares are held by institutional investors. 32.9% of Avacta Group shares are held by company insiders. Comparatively, 18.2% of Ergomed shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Ergomed has a net margin of 9.87% compared to Avacta Group's net margin of -114.45%. Ergomed's return on equity of 18.08% beat Avacta Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Avacta Group-114.45% -73.02% -21.80%
Ergomed 9.87%18.08%10.16%

In the previous week, Avacta Group's average media sentiment score of 0.67 beat Ergomed's score of 0.00 indicating that Avacta Group is being referred to more favorably in the media.

Company Overall Sentiment
Avacta Group Positive
Ergomed Neutral

Summary

Ergomed beats Avacta Group on 10 of the 14 factors compared between the two stocks.

Get Avacta Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for AVCT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AVCT vs. The Competition

MetricAvacta GroupBiotechnology IndustryMedical SectorLON Exchange
Market Cap£193.48M£159.96M£5.40B£1.59B
Dividend Yield3.97%3.39%5.13%11.05%
P/E Ratio-600.00348.23113.461,740.37
Price / Sales8.5519,593.141,484.40230,520.65
Price / Cash15.0011.1439.6435.87
Price / Book3.867.754.652.88
Net Income-£25.89M-£18.69M£119.06M£144.83M
7 Day Performance-3.57%0.01%0.79%0.11%
1 Month Performance22.17%2.54%5.65%-0.11%
1 Year Performance-61.57%27.91%36.76%15.28%

Avacta Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AVCT
Avacta Group
N/AGBX 54
+8.0%
N/A-62.2%£193.48M£22.62M-600.00120
ERGO
Ergomed
N/AGBX 1,346
flat
N/A+0.2%£701.00M£152.09M4,641.386
SLN
Silence Therapeutics
N/AGBX 535
-0.9%
N/A+0.0%£480.35M£11.35M-11.01100Positive News
High Trading Volume
OXB
Oxford Biomedica
0.6228 of 5 stars
GBX 414.26
-2.4%
GBX 433.33
+4.6%
+96.8%£436.46M£97.28M-287.68891News Coverage
PRTC
PureTech Health
N/AGBX 153.20
+0.5%
N/A+4.0%£366.79M£3.33M-666.09300Gap Up
HZD
Horizon Discovery Group plc (HZD.L)
N/AGBX 184.50
flat
N/A+0.0%£302.98M£54.63M-33.55416
VRP
Verona Pharma plc (VRP.L)
N/AGBX 55
+5.8%
N/A+0.0%£228MN/A-1.6822News Coverage
Gap Up
FARN
Faron Pharmaceuticals Oy
N/AGBX 177.33
+1.3%
N/A-34.4%£185.52M£-725,000.00-554.1634Gap Down
ARIX
Arix Bioscience
N/AGBX 142
flat
N/A+21.9%£183.73M£14.16M1,290.919
HVO
hVIVO
N/AGBX 26.45
-0.2%
N/A+45.3%£179.96M£67.21M881.67N/APositive News
4BB
4basebio
N/AGBX 1,285
-4.8%
N/A+158.0%£164.61M£311,000.00-1,647.44101News Coverage

Related Companies and Tools


This page (LON:AVCT) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners